NASDAQ:ONC
BeOne Medicines Ltd.
BeOne Medicines Ltd.'s revenue grew 40.2% in fiscal 2025 to $5.3B while operating margin rose to 8.4%, its highest in 10 years. Free cash flow was $941.7M, 17.6% of revenue, and the diluted share count rose 7.8%.Summary generated from BeOne Medicines Ltd.'s SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$5.3B
Revenue growth+40.2%
Revenue, 5-yr CAGR+76.8%
Gross margin87.5%
Operating margin8.4%
Net margin5.4%
ROIC25.8%
Return on equity7.5%
Debt / equity0.19
Free cash flow$941.7M
FCF margin17.6%
Share count change+7.8%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1,176 | 1,416 | 2,459 | 3,810 | 5,343 |
| Operating income | −1,439 | −1,790 | −1,208 | −568 | 447 |
| Net income | −1,458 | −2,004 | −882 | −645 | 287 |
| Free cash flow | −1,562 | −1,822 | −1,719 | −633 | 942 |
Recent filings
- 4Insider transaction report
Oct 2, 2026 - 4Insider transaction report
Sep 30, 2026 - 8-KResults of operations and financial condition
Aug 26, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 5, 2026 - 8-KResults of operations and financial condition
Aug 5, 2026 - 8-KOther events
Jun 26, 2026 - 8-KDirector or officer change
Jun 11, 2026 - 8-KOther events
May 15, 2026